Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of a warm, shiny sun and cool breeze wafting through the unusually quiet Pharmalot campus. Our Pharmalittles, you see, are sleeping in. Of course, a cup or two of stimulation also helps steady the nerves. Our choice today is almond toffee, for those who track such things. So, time to get cracking. On that note, here are some tidbits to help you along. Hope your day goes well and you conquer the world …

Mylan (MYL) is evaluating “a wide range of alternatives” because it believes the public markets undervalue the company, although no timetable was given for any action. In explaining its decision, the company noted its international business, which is expected to continue growing, now represents more than 60 percent of global sales. By contrast, there are “negative trends and dynamics” in the U.S. market, which Mylan believes are “unsustainable for the health care system over the long-term.” The drug maker missed second quarter financial targets and cut 2018 guidance.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • To hark back ‘half a century’ (plus 1) to “the summer of love,” the GW Pharma offering at that price would have garnered the comment – “D$%n, that must be REALLY good s!*t!”

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy